SEC Filings
Akebia Swings To $14.4 Million Loss Despite Vafseo's Growing Patient Count
Auryxia sales fell under pressure from generic competition, while inventory reductions limited Vafseo revenue.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
Auryxia sales fell under pressure from generic competition, while inventory reductions limited Vafseo revenue.
Earnings
CEO Harvey M. Schwartz pointed to strong distributable earnings and almost $100 billion returned to fund investors since early 2024.
Markets
A terminated customer program costs approximately $12 million in fourth-quarter revenue, limiting a higher growth outlook.
SEC Filings
The biotech plans a late-stage abdakibart trial in the first half of 2027; higher operating costs accompanied a narrower quarterly loss.
Earnings
The animal-health company raised its adjusted earnings outlook but cut its standard-accounting forecast as quarterly revenue slipped.
Deals
Acquired sales lifted quarterly revenue, but continuing-operations profit fell and management trimmed its adjusted earnings outlook.
Markets
The vaccine maker returned to quarterly profit and now expects 2026 revenue growth of 15% to 25%.
Earnings
The projection uses current power-price curves, while management seeks projects that can deliver better returns than share repurchases.
Markets
The drugmaker entered Friday up 67% this year, with a higher revenue forecast and plans for a late-stage thyroid trial.
Markets
The power producer expanded its buyback authorization, while management tied its growth projection to roughly $3 billion in annual repurchases.
SEC Filings
Traffic rose 0.8%, but restaurant margins narrowed even as lower food costs helped offset spending on labor and delivery.
SEC Filings
The company plans to use existing cash for the purchase, leaving approximately $493 million of buyback authorization.